Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice
Tatva Chintan Pharma Chem receives export order worth $35, 55,000
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond
Subscribe To Our Newsletter & Stay Updated